Plain-English translation of NCT01607905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Glioblastoma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested a new drug called in patients with advanced cancer that had spread or was difficult to treat. Researchers gave participants the medication by mouth at different dose levels to understand how safe it was and how their bodies handled it. The study also looked for early signs that the treatment might work against their cancer.
Many patients with advanced solid tumors have limited treatment options after standard therapies stop working. This medication was being studied because it works through a new mechanism that researchers believed might help fight cancer cells, and the trial aimed to find the right dose that balances safety with potential benefit.
Participants took the medication by mouth according to one of eight different schedules, which varied in how often they took it each week and how many doses per cycle (typically 28 days). The trial started with lower doses and gradually increased them in different groups to find the safest level. Participants attended regular visits for blood tests, imaging scans, and check-ins to monitor how they responded and any side effects they experienced.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Canada